Topic: Value-Based Pricing

  • Medicare Must Study Unproven, Expensive Alzheimer’s Drug

  • Value-Based Management of Specialty Drugs: Practical Considerations and Implications for Pharmacy

  • CMS’s Proposed Medicaid Best Price Loophole for Value-Based Purchasing of Drugs

  • Pharmaceutical Products and Their Value: Lessons Learned and the Path Ahead

  • The Conflict Between QALYs and Well-Funded Patient Advocacy Groups

  • Blueprints for Indication-Specific Pricing

    Blueprints for Indication-Specific Pricing

  • Pharmaceutical Products and Their Value

    Pharmaceutical Products and Their Value

  • Cardiovascular Drugs Not Price Aligned with Value in US

  • Outcomes-Based Drug Contracts Do Not Move Us Closer to Value

    Outcomes-Based Drug Contracts Do Not Move Us Closer to Value

  • Value-Based Pricing for Drugs: Theme and Variations

    Value-Based Pricing for Drugs: Theme and Variations